184 related articles for article (PubMed ID: 26510854)
21. PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
Blazquez R; Wlochowitz D; Wolff A; Seitz S; Wachter A; Perera-Bel J; Bleckmann A; Beißbarth T; Salinas G; Riemenschneider MJ; Proescholdt M; Evert M; Utpatel K; Siam L; Schatlo B; Balkenhol M; Stadelmann C; Schildhaus HU; Korf U; Reinz E; Wiemann S; Vollmer E; Schulz M; Ritter U; Hanisch UK; Pukrop T
Glia; 2018 Nov; 66(11):2438-2455. PubMed ID: 30357946
[TBL] [Abstract][Full Text] [Related]
22. Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.
Criscitiello C; Viale G; Curigliano G; Goldhirsch A
Breast Cancer (Dove Med Press); 2018; 10():23-29. PubMed ID: 29430197
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
24. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Baselga J
Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
[TBL] [Abstract][Full Text] [Related]
25. Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function.
Blanco B; Herrero-Sánchez C; Rodríguez-Serrano C; Sánchez-Barba M; Del Cañizo MC
Int Immunopharmacol; 2015 Sep; 28(1):675-85. PubMed ID: 26256696
[TBL] [Abstract][Full Text] [Related]
26. Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors.
Toska E; Baselga J
Clin Cancer Res; 2016 May; 22(9):2099-101. PubMed ID: 26957555
[TBL] [Abstract][Full Text] [Related]
27. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
Hu Y; Guo R; Wei J; Zhou Y; Ji W; Liu J; Zhi X; Zhang J
Cell Death Dis; 2015 Dec; 6(12):e2020. PubMed ID: 26673665
[TBL] [Abstract][Full Text] [Related]
28. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
[TBL] [Abstract][Full Text] [Related]
29. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
Bukum N; Novotna E; Morell A; Hofman J; Wsol V
Chem Biol Interact; 2019 Apr; 302():101-107. PubMed ID: 30703376
[TBL] [Abstract][Full Text] [Related]
30. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
McKay RR; De Velasco G; Werner L; Bellmunt J; Harshman L; Sweeney C; Rosenberg JE; Hirsch M; Signoretti S; Van Allen EM; Walsh M; Vaishampayan U; McDermott DF; Choueiri TK
Cancer; 2016 Aug; 122(15):2389-98. PubMed ID: 27198170
[TBL] [Abstract][Full Text] [Related]
31. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
Saura C; Bendell J; Jerusalem G; Su S; Ru Q; De Buck S; Mills D; Ruquet S; Bosch A; Urruticoechea A; Beck JT; Di Tomaso E; Sternberg DW; Massacesi C; Hirawat S; Dirix L; Baselga J
Clin Cancer Res; 2014 Apr; 20(7):1935-45. PubMed ID: 24470511
[TBL] [Abstract][Full Text] [Related]
32. PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway.
Ren Y; Zhou X; Qi Y; Li G; Mei M; Yao Z
Oncol Rep; 2012 Sep; 28(3):943-8. PubMed ID: 22710837
[TBL] [Abstract][Full Text] [Related]
33. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
Coughlin CM; Johnston DS; Strahs A; Burczynski ME; Bacus S; Hill J; Feingold JM; Zacharchuk C; Berkenblit A
Breast Cancer Res Treat; 2010 Nov; 124(1):1-11. PubMed ID: 20803067
[TBL] [Abstract][Full Text] [Related]
34. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
35. PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.
Yang MH; Chen IC; Lu YS
J Formos Med Assoc; 2019 Sep; 118(9):1333-1338. PubMed ID: 30577988
[TBL] [Abstract][Full Text] [Related]
36. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
37. Buparlisib is a brain penetrable pan-PI3K inhibitor.
de Gooijer MC; Zhang P; Buil LCM; Çitirikkaya CH; Thota N; Beijnen JH; van Tellingen O
Sci Rep; 2018 Jul; 8(1):10784. PubMed ID: 30018387
[TBL] [Abstract][Full Text] [Related]
38. ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
Hermanto U; Zong CS; Wang LH
Oncogene; 2001 Nov; 20(51):7551-62. PubMed ID: 11709727
[TBL] [Abstract][Full Text] [Related]
39. Novel targeted agents for the treatment of advanced breast cancer.
de la Vega M; Díaz-Cantón E; Alvarez RH
Future Med Chem; 2012 May; 4(7):893-914. PubMed ID: 22571614
[TBL] [Abstract][Full Text] [Related]
40. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
